Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ram Selvaraju maintains $Genmab(GMAB.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 40.8% and a
Optimistic Buy Rating for Genmab on Promising Acasunlimab Clinical Data and Future Growth Potential
Genmab Announces Strategic Financial Updates
6-K: Report of foreign private issuer (related to financial reporting)
Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target
UBS Sticks to Their Buy Rating for Genmab A/S (0MGB)
Maintaining Hold on Genmab: Awaiting Detailed Data on Rina-S's Market Potential
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Aviceda Therapeutics Announces Addition of Erin Lavelle to Board of Directors
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $50
Truist Financial analyst Asthika Goonewardene maintains $Genmab(GMAB.US)$ with a buy rating, and adjusts the target price from $53 to $50.According to TipRanks data, the analyst has a success rate
Genmab (GMAB) Gets a Buy From Truist Financial
Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley analyst Vikram Purohit maintains $Genmab(GMAB.US)$ with a hold rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 37.5% and a
Morgan Stanley Reinstates Equal-Weight on Genmab, Announces $31 Price Target
Morgan Stanley Upgrades Genmab(GMAB.US) to Hold Rating, Cuts Target Price to $31
Morgan Stanley analyst Vikram Purohit upgrades $Genmab(GMAB.US)$ to a hold rating, and adjusts the target price from $32 to $31.According to TipRanks data, the analyst has a success rate of 39.3%
Genmab's Hold Rating: Balancing Stability and Uncertainty
Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Strong Pipeline and Regulatory Approval Prospects Affirm Buy Rating for Genmab
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference